We announce 10 new grants totaling over $2.6 million to drive promising new approaches to treating and diagnosing Alzheimer’s and related dementias.
11th annual gala raises $2.5 million for lifesaving Alzheimer's treatments
We raised over $350,000 for life-saving research at our Seventh Annual Great Ladies Luncheon & Fashion Show at the Ritz-Carlton Washington, D.C., which honored author Sally for her work in the fight against Alzheimer’s.
A new investment of $300,000 in Oryzon Genomics continues our support of its groundbreaking epigenetic drug ORY-2001.
A team of scientists from the Medical Research Council (MRC) in the UK have found two drugs, which block brain cell death and prevent neurodegeneration in preclinical studies. Their findings were published today in Brain.
Our new investment in M3 Biotechnology is advancing its drug program toward clinical trials
We recently awarded eight new grants totaling over $4 million to advance treatments for Alzheimer’s and related dementias. Several of the awards support new approaches to treating these diseases.
We have been chosen as Official Charity Partner of the TCS New York City Marathon for the third year. The race will take place on Sunday, November 5, 2017.
ADDF and Harrington Institute increase funding and resources for promising Alzheimer’s drug discovery programs.
Our Board of Governors has appointed Mark Roithmayr as Chief Executive Officer. Mr. Roithmayr is the first person to hold the CEO position at the ADDF.